Literature DB >> 17898807

International comparisons of survival from lung cancer: pitfalls and warnings.

Sara C Erridge1, Henrik Møller, Allan Price, David Brewster.   

Abstract

Population-based survival data can provide valuable comparative data on outcome but should be interpreted with caution. Differences in data collection and analysis, patient and tumor characteristics and treatment options can have an impact on reported results. Ideally, data from the whole population, including clinical-only diagnoses, should be reported and the methods of case identification described. The relative survival rates should preferably be given. Data on patient characteristics such as age, sex, ethnicity and socioeconomic deprivation should be described, together with tumor details such as pathology and clinical stage. Whenever possible, details on the use of treatments should be reported.

Entities:  

Mesh:

Year:  2007        PMID: 17898807     DOI: 10.1038/ncponc0932

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  16 in total

1.  Asperfuranone from Aspergillus nidulans inhibits proliferation of human non-small cell lung cancer A549 cells via blocking cell cycle progression and inducing apoptosis.

Authors:  Clay C C Wang; Yi-Ming Chiang; Mike B Praseuth; Po-Lin Kuo; Hsin-Lin Liang; Ya-Ling Hsu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-02-09       Impact factor: 4.080

2.  Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort.

Authors:  S C Erridge; M G Hart; G R Kerr; C Smith; S McNamara; R Grant; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

3.  Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.

Authors:  Yanmei Zou; Xiaomin Qin; Hua Xiong; Feng Zhu; Tao Chen; Hongge Wu
Journal:  Tumour Biol       Date:  2015-02-05

4.  Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells.

Authors:  Jiunn-Min Shieh; Tai-An Chiang; Wen-Teng Chang; Chang-Hung Chao; Yi-Chieh Lee; Guan-Yu Huang; You-Xin Shih; Yuan-Wei Shih
Journal:  Mol Cell Biochem       Date:  2009-09-21       Impact factor: 3.396

5.  Ent-11α-Hydroxy-15-oxo-kaur-16-en-19-oic-acid Inhibits Growth of Human Lung Cancer A549 Cells by Arresting Cell Cycle and Triggering Apoptosis.

Authors:  Li Li; George G Chen; Ying-Nian Lu; Yi Liu; Ke-Feng Wu; Xian-Ling Gong; Zhan-Ping Gou; Ming-Yue Li; Nian-Ci Liang
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

6.  5-demethyltangeretin inhibits human nonsmall cell lung cancer cell growth by inducing G2/M cell cycle arrest and apoptosis.

Authors:  Noppawat Charoensinphon; Peiju Qiu; Ping Dong; Jinkai Zheng; Pearline Ngauv; Yong Cao; Shiming Li; Chi-Tang Ho; Hang Xiao
Journal:  Mol Nutr Food Res       Date:  2013-08-08       Impact factor: 5.914

Review 7.  The role of cancer registries in cancer control.

Authors:  Donald Maxwell Parkin
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

8.  Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.

Authors:  Hongqin Zhuang; Weiwei Jiang; Xiangyu Zhang; Fan Qiu; Ziyi Gan; Wei Cheng; Jing Zhang; Shengwen Guan; Bo Tang; Qilai Huang; Xinhua Wu; Xiaofeng Huang; Wenhui Jiang; Qingang Hu; Min Lu; Zi-Chun Hua
Journal:  J Mol Med (Berl)       Date:  2012-09-05       Impact factor: 4.599

9.  Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway.

Authors:  Xiaoman Xu; Yi Zhang; Dan Qu; Tingshu Jiang; Shengqi Li
Journal:  J Exp Clin Cancer Res       Date:  2011-03-29

10.  Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro.

Authors:  Xiao-Man Xu; Yi Zhang; Dan Qu; Hong-Bo Liu; Xiu Gu; Guang-Yu Jiao; Li Zhao
Journal:  Exp Ther Med       Date:  2013-01-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.